BGMS - Cyclacel Pharmaceuticals, Inc.

1.18
-0.005   -0.424%

Share volume: 164,530
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$1.18
-0.01
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 4%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
12.38%
1 Month
14.55%
3 Months
-15.11%
6 Months
-52.80%
1 Year
423.05%
2 Year
-32.57%
Key data
Stock price
$1.18
P/E Ratio 
0.00
DAY RANGE
$1.16 - $1.26
EPS 
-$2.47
52 WEEK RANGE
$0.22 - $19.87
52 WEEK CHANGE
$412.60
MARKET CAP 
11.061 M
YIELD 
N/A
SHARES OUTSTANDING 
4.900 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$156,189
AVERAGE 30 VOLUME 
$174,954
Company detail
CEO: Spiro Rombotis
Region: US
Website: cyclacel.com
Employees: 14
IPO year: 2004
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cyclacel Pharmaceuticals, Inc. develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) and CYC140. Sapacitabine, a nucleoside analog that is orally available prodrug of CNDAC, is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome.

Recent news